Skip to main content
Clinical Trials/NCT03397420
NCT03397420
Completed
N/A

Effect of Family-centered Model of HIV Care (FAM-CARE) on Viral Suppression and Retention in Care of HIV-positive Children in Swaziland

Elizabeth Glaser Pediatric AIDS Foundation1 site in 1 country742 target enrollmentSeptember 13, 2017
ConditionsHIV Infections

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV Infections
Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Enrollment
742
Locations
1
Primary Endpoint
Proportion of HIV-positive children on ART virally suppressed
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The study will evaluate the effect of implementing a family-centered care (FAM-CARE) program (where all HIV-positive family members are seen together as a unit and receive care together) on viral suppression and retention in HIV-positive children <15 years through enrollment of a prospective cohort of 660 HIV-positive children and their caregivers at sites that were randomized to either implement the family-care program (intervention sites) or continue the current standard of care (control sites).

Detailed Description

The proposed study will evaluate the effect of implementing a FAM-CARE program on viral suppression and retention in children through enrollment of a prospective cohort of HIV-positive children and their caregivers at sites implementing the FAM-CARE program and control sites continuing the current standard of care. The study will be conducted in four "clusters" of facilities (2 hospitals and 2 health centers and their filter clinics) in the Hhohho region of Swaziland. Two facility "clusters" (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program with viral load monitoring and two "clusters" (one hospital and one health center, with their filter clinics) will be control standard-of care sites. A prospective cohort of HIV-positive children and their caregivers will be followed in the FAM-CARE program sites and control sites. Each child will be followed for 18 months following enrollment. The primary objective is to evaluate the effect of the FAM-CARE program on the rates of viral suppression and retention in care, comparing rates of viral suppression and retention in children enrolled in FAM-CARE versus control sites. The study will also evaluate factors associated with viral suppression and retention (including family demographic characteristics), and conduct qualitative interviews to assess the acceptability of the FAM-CARE program by caregivers and health care providers in the intervention sites.

Registry
clinicaltrials.gov
Start Date
September 13, 2017
End Date
July 30, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • HIV-positive child aged \<15 years receiving HIV care at the study facility.

Exclusion Criteria

  • At least one family member residing in the household is also HIV-positive and is receiving services at the study facility

Outcomes

Primary Outcomes

Proportion of HIV-positive children on ART virally suppressed

Time Frame: 18 months after study enrollment.

Proportion of HIV-positive children on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay detection) and the proportion with HIV RNA \<1,000 copies/mL at 18 months after enrollment

Proportion of HIV-positive on ART virally unsuppressed

Time Frame: 18 months after study enrollment.

Proportion of HIV-positive children on ART with HIV RNA \>1000 copies/mL 18 months after enrollment into the study.

Secondary Outcomes

  • Loss to follow-up(18 months after study enrollment)
  • Proportion HIV-positive children on ART virally suppressed (<1,000 copies/mL of HIV RNA) at 6 and 12 months after study enrollment(6 and 12 months after study enrollment)
  • Acceptability of the FAM-CARE program based on individual interview responses(18 months after study enrollment)
  • Factors associated with HIV viral suppression(18 months after study enrollment)
  • ART initiation(18 months after study enrollment)

Study Sites (1)

Loading locations...

Similar Trials